Chise Profile picture
Apr 26, 2021 14 tweets 5 min read Read on X
Cell-mediated immunity wins! A new study highlights the robust nature and kinetics of T-cell priming by SARS-CoV-2 mRNA vaccines. Why does this matter? Long-term antiviral immunity that is likely to ensure lasting protection against SARS-CoV-2 infection!
biorxiv.org/content/10.110…
Firstly, T-cells that specifically respond to SARS-CoV-2 DO get activated by these vaccines! Researchers saw priming of both CD4+ and CD8+ T-cells with mRNA vaccination. CD4+ response wasn’t only rapid, it was universal. All participants responded after their 1st dose regardless
of whether or not they had a previous SARS-CoV-2 infection. CD4+ T-cells are considered "helper" cells because they do not neutralize infections but rather trigger the body's response to infections. CD8+ response developed more gradually. CD8+ T-cells, also known as "killer T-
cells", are cytotoxic- this means that they are able to directly kill virus-infected cells. You want these guys on your side. Researchers saw about 85% of participants who had never COVID had detectable SARS-CoV-2-specific CD8+ T-cells after the 2nd dose. No significant boosting
of CD8+ cells occurred for recovered individuals. Another important point was that researchers saw NO decline in T-cell responses regardless of age! Just because antibody (B-cell) response may not be high for some DOES NOT mean your T-cells won’t be there to protect you!
So now that we know these T-cell responses are present, let’s discuss. If you haven’t read my precious post on immunological memory, please be sure to do so- it’ll help. Researchers realized the T-cell responses initiated by the vaccines appear to indeed have characteristics of
long-lived memory cells (CD45RA- CD27+), falling in central memory and EM1 subsets, which resembles the memory response to SARS-CoV-2 infection. Why does this matter? It matters because it demonstrates your immune system is going to remember how to fight this virus off should it
come into contact with this virus again, and that includes it’s variants. Researchers also observed Th1 and T follicular helper (Tfh) cells by the vaccine, were the same helper cells activated during natural SARS-CoV-2 infection. These guys are a specialized subset of CD4+
T-cell that play a critical role in protective immunity helping B-cells produce antibody against foreign pathogens. These DO matter. Why? Th1 and Tfh cells help the maturation of CD8+ T-cells and B-cells (antibody response), respectively.
Researchers observed Th1 cells primed by the 1st dose strongly correlated with CD8+ responses to the 2nd dose, and the same for Tfh with neutralizing antibodies. This means that CD4+ T-cell responses to the 1st dose play a key part in the developing immune response to the 2nd
dose! Early priming of CD4+ T-cells may be critical to one’s overall immunity generated by vaccination. This is why we express the importance of both doses in naive individuals! Correlation, correlation, correlation, my friends.
Lastly, researchers compiled these reposted into a UMAP to visualize the overall immune responses against SARS-CoV-2. Their analysis revealed a dynamic and coordinated immune response to vaccination and demonstrates the importance of both doses for those who have not had a
previous SARS-CoV-2 infection to achieve optimal immunity, while only a single dose could be necessary for those who have previously recovered from one. TLDR:
•T-cells ARE activated by the vaccines
•Vaccination induced rapid near-maximal antigen-specific CD4+ T-cell responses
after 1st dose
•CD8+ T-cell responses develop gradually after 1st and 2nd dose
•Vaccine-elicited immune response demonstrates key hallmarks of long-term antiviral immunity- which means long lasting protection against SARS-CoV-2!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Chise

Chise Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Oct 28, 2024
THIS IS HUGE! An HIV PrEP drug candidate in the form of a twice-yearly subcutaneous injection has been shown to reduce HIV infections by 96% in a SECOND late-stage Phase III trial. Lenacapavir was 99.9% effective at preventing HIV in MORE THAN 2,000 participants.🧵⬇️
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
Read 13 tweets
Oct 24, 2024
So, not COVID related BUT, this is REALLY exciting news. Phase I/II data shows Moderna’s Norovirus vaccine candidate mRNA-1403, has shown early signs of efficacy AND elicited robust serum HBGA-blocking antibody responses against ALL THREE NoV genotypes. Let’s talk about that!🧵⬇️
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomized, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections.
As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden. Symptoms include vomiting and diarrhoea, which can be severely dehydrating, and the risk of severe outcomes from NoV is greatest in young children and older
Read 16 tweets
Oct 21, 2024
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that!🧵⬇️
The research has been published in Cancer Letters. Yes, it is PEER-REVIEWED.
sciencedirect.com/science/articl…Key Takeaways:  •RK-33 targets DDX3, an RNA helicase elevated in cancer cells, to inhibit breast cancer bone metastasis.  •In mouse models, RK-33 eliminated bone metastases and prevented further cancer spread without significant adverse effects.  •The study suggests RK-33 as a promising treatment for breast cancer bone metastasis, urging further research into its broader applications.
In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown to help treat other types of cancer and viral illnesses.
Read 14 tweets
Oct 17, 2024
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧵⬇️
The research has been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Yes, it is PEER-REVIEWED.
•~ alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…What You Need to Know ⬇️  •Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease.  •The drug, a peptide inhibitor called RI-AG03, successfully prevented the build-up of toxic tau proteins in both laboratory and fruit fly studies.  •Although further research is necessary, including clinical trials in humans, this research contributes to the advancement of more effective therapies for neurodegenerative diseases.  •There are two main “hotspots” on the tau protein, where fibril clumping occurs. In this new study, research...
Tau proteins are essential for maintaining the structure and function of neurons. However, in Alzheimer’s disease, these proteins malfunction and aggregate into long, twisted fibrils. As these fibrils build up, they form neurofibrillary tangles- masses of tangled tau proteins
Read 15 tweets
Oct 9, 2024
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧵⬇️
The study has been published in Science. Yes, it is PEER-REVIEWED.
science.org/doi/10.1126/sc…Model figure. (A) C. difficile toxins target the intestinal epithelium and cause severe pathology and gastrointestinal disease leading to morbidity and mortality. (B) When vaccinated mice are infected with C. difficile, anti-toxin IgG and IgA protect mice from disease and inclusion of PPEP-1 and CdeM as immunogens improves decolonization of toxigenic C. difficile from the gastrointestinal tract. Credit: Science (2024). DOI: 10.1126/science.adn4955
The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals-
Read 15 tweets
Oct 5, 2024
THIS IS HUGE! Scientists at the University of Oxford are developing the world's FIRST ovarian cancer vaccine that could potentially wipe the disease out. OvarianVax teaches the immune system to recognize and attack the earliest stages of ovarian cancer. Let’s talk about that!🧵⬇️
The hope is that individuals could receive the vaccine preventatively with the goal of eradicating the disease. Researchers have suggested it could work in a similar way to the human papillomavirus (HPV) vaccine, which is on track to stamp out cervical cancer.
Oxford researchers are designing OvarianVax, a vaccine which teaches the immune system to recognize and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(